|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alternativeTo
|
gptkb:tricyclic_antidepressants
gptkb:SSRIs
|
|
gptkbp:category
|
antiparkinsonian agent
antidepressant
|
|
gptkbp:contraindication
|
gptkb:tricyclic_antidepressants
gptkb:SSRIs
sympathomimetic drugs
|
|
gptkbp:designer
|
some are reversible
|
|
gptkbp:discoveredIn
|
1950s
|
|
gptkbp:effect
|
increase levels of dopamine
increase levels of norepinephrine
increase levels of serotonin
|
|
gptkbp:example
|
gptkb:isocarboxazid
gptkb:phenelzine
gptkb:rasagiline
gptkb:tranylcypromine
gptkb:selegiline
|
|
gptkbp:firstLine
|
not usually first-line
|
|
gptkbp:fullName
|
Monoamine oxidase inhibitors
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MAO inhibitors
|
|
gptkbp:interactsWith
|
gptkb:dextromethorphan
gptkb:linezolid
gptkb:meperidine
decongestants
tyramine-containing foods
|
|
gptkbp:irreversible
|
some are irreversible
|
|
gptkbp:legalStatus
|
regulated
|
|
gptkbp:mechanismOfAction
|
inhibit monoamine oxidase enzyme
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
drug-food interaction
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
|
|
gptkbp:sideEffect
|
weight gain
insomnia
sexual dysfunction
hypertensive crisis with tyramine
|
|
gptkbp:target
|
gptkb:MAO-A
gptkb:MAO-B
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:depression
anxiety disorders
|
|
gptkbp:usedIn
|
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:bulimia_nervosa
treatment-resistant depression
atypical depression
|
|
gptkbp:bfsParent
|
gptkb:Zoloft
|
|
gptkbp:bfsLayer
|
5
|